Genenta Science (NASDAQ:GNTA) Stock Price Down 1.3% – Here’s Why

Shares of Genenta Science S.p.A. (NASDAQ:GNTA) were down 1.3% during mid-day trading on Friday . The company traded as low as $3.51 and last traded at $3.76. Approximately 22,483 shares changed hands during mid-day trading, an increase of 43% from the average daily volume of 15,753 shares. The stock had previously closed at $3.81.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Genenta Science in a research note on Wednesday, October 2nd.

Genenta Science Price Performance

The company’s fifty day moving average is $4.88 and its two-hundred day moving average is $4.56.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Genenta Science stock. AlTi Global Inc. bought a new position in shares of Genenta Science S.p.A. (NASDAQ:GNTA) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned 1.10% of Genenta Science as of its most recent SEC filing. Institutional investors and hedge funds own 15.13% of the company’s stock.

Genenta Science Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.